Latest "Zenobia Therapeutics" News Stories - Page: 20

09:05 EST 18th November 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 476–500 of 7,900+

Probably Relevant

G1 Therapeutics nets $170mm through public offering

G1 Therapeutics Inc. netted $170mm through the public sale of 3mm common shares at $60. The company develops drugs for cancer...

Small-Cap Snapshot: Insys Therapeutics stock rises thanks to dose of optimistic news from the US FDA

Small-cap names on the move today are: Insys Therapeutics (NASDAQ:INSY), AgEagle Aerial Systems Inc (NYSE American: UAVS), Reis Inc (NASDAQ:REIS), Kirkland’s Inc (NASDAQ: KIRK). 

Bone Therapeutics: A unique approach to the development of cell therapy products for bone fracture repair & fracture prevention.

Bone Therapeutics is a biotechnology company with a unique approach to the development of cell therapy products for bone fracture repair and fracture prevention. Bone Therapeutics is creating a new and unique treatment approach using differentiated bone-forming cells administered via a minimally invasive percutaneous procedure, that is expected to offer significant benefits over the current stand...

Novelion Therapeutics Inc.: Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions

Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic m...

Carisma Therapeutics raises $53mm through Series A

Carisma Therapeutics Inc. (cancer immunotherapies) raised $53mm through its Series A venture round. AbbVie Ventures and Healt...

28-7 Therapeutics Raises $65 Million to Advance Tumor Suppressor Research

Twentyeight-Seven Therapeutics (28-7), announced it had completed a $65 million Series A financing. It was co-led by founding investor MPM Capital and Novartis Venture Fund. Joining them were Johnson & Johnson Innovation – JJDC, Vertex Ventures, Longwood Fund, and Astellas Venture Management.

Cardiol Therapeutics Closes CDN$10.5 Million Private Placement; #Nanotherapeutics

Toronto, Ontario - May 24, 2018 (Newsfile Corp.) ( Newswire) Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart

iTeos Therapeutics Closes on $75 Million Series B Financing

Belgium-based iTeos Therapeutics SA completed an oversubscribed Series B financing worth $75 million.

Karus Therapeutics CEO Simon Kerry discusses the company's focus on PI3 Kinase and HDAC6 inhibitor programmes.

Simon Kerry the CEO of the Oxfordshire based company Karus Therapeutics, talks with Fintan Walton about the company's work to develop innovative medicines for the treatment of inflammatory disease and cancer.

Sangamo to acquire TxCell for €65.8mm

Sangamo Therapeutics Inc. will pay €65.8mm ($77mm; €2.58 per share, a 175% premium) to acquire privately held T-cell immu...

Global Outlook for the Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022 – Rising Number of Patients Opting for Chemotherapy –

DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022” report has been added to’s offering. The Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022. The report has been prepared based on an … Continue reading → Cet article Globa...

Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA

Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced findings from three post-hoc analyses of data from the Phase 3 clinical trial of LUXTURNA (voretigene neparvovec-rzyl) at the American Academy of Ophthalmology Annual Meeting in Chicago. As quoted in the press release: LUXTURNA is R...

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million. And like Juno, Allogene is working with a live immune-cell treatment called CAR-T, but it is harvesting cells […]

Orchard Therapeutics receives Rare Pediatric Disease Designation from FDA

Orchard Therapeutics, a commercial stage company, has been granted a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its gene therapy candidate, OTL-200, for the treatment of patients with MLD

Sarepta Therapeutics-Aktie: weitere Outperformance trotz Kurssteigerungen!

Toronto ( - Sarepta Therapeutics-Aktienanalyse des Analysten Brian Abrahams von RBC Capital Markets: Analyst Brian Abrahams vom Investmenthaus RBC Capital Markets bestätigt laut ...

Acorda Therapeutics Has One Bad Week With Loss of Patents and Delayed FDA Review

Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. FDA's decision to delay a ruling for its Parkinson’s disease treatment.

Digital therapeutics company Click brings in $17mm in Sanofi Ventures-led round

Click Therapeutics Inc. (developing software as prescription medicines) raised $17mm in an undisclosed round led by Sanofi Ve...

Digital therapeutics company Click brings in $17mm through Sanofi Ventures-led round

Click Therapeutics Inc. (developing software as prescription medicines) raised $17mm in an undisclosed round led by Sanofi Ve...

Antisense Therapeutics Limited: First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy

MELBOURNE, AUSTRALIA / ACCESSWIRE / August 29, 2018 / Antisense Therapeutics (ASX: ANP) today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL...

Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline ...

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline Read more...

Radimmune Therapeutics Selected Goodwin Biotechnology for Process Development through cGMP ...

PLANTATION, Fla., Nov. 14, 2018 /PRNewswire/ -- Radimmune Therapeutics has selected Goodwin Biotechnology, Inc. to develop a process and manufacture it's lead therapeutic oncology candidate Read more...

Therapeutics and collaboration in the spotlight at Technology Showcase

This year’s Technology Showcase, held on 13 June at Oxford’s Saïd Business School, attracted a host of leading academics, clinicians and investors to discuss the most exciting commercial opportunities and projects in the field of Therapeutics, Small Molecules and Biologics. The event, which was attended by around 200 people, was organised by the NIHR Oxford BRC, ... Read more

United Therapeutics Pays $800 Million Upfront for Rights to Arena's Experimental PAH Drug Ralinepag

NewsUnder the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture, and commercialize Ralinepag.

Dr. Bob Raffa Joins Bridge Therapeutics' Scientific Advisory Board Bring Decades of Research ...

BIRMINGHAM, Ala., Sept. 21, 2018 /PRNewswire/ -- Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. Read more...

Carrick Therapeutics in─licenses exclusive worldwide rights to develop and commercialise ovarian cancer drug from BTG

Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, has licensed exclusive worldwide rights to develop and

Quick Search


News Quicklinks